Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 65162-370

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 65162-370). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Fomula (Fesoterodine Fumarate Extended Release Tablets 1)

Chemical structure of Fesoterodine Fumarate, showing molecular components including aromatic rings, hydroxyl, and ester groups.*

FDA Label Image

Figure 1 (Fesoterodine Fumarate Extended Release Tablets 2)

A line graph titled "Change in Number of Micturitions per 24 h (Study 1)" showing mean change from baseline over 12 weeks. The x-axis represents weeks (0 to 12) and the y-axis shows mean change in number of micturitions per 24 hours (0.0 to -3.0). It compares three groups: placebo (dotted line with circles), Fesoterodine fumarate 4 mg (dashed line with triangles), and Fesoterodine fumarate 8 mg (solid line with squares). Both Fesoterodine groups show greater reductions in micturitions than placebo.*

FDA Label Image

Figure 2 (Fesoterodine Fumarate Extended Release Tablets 3)

A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' showing mean change from baseline in urge incontinence episodes over 12 weeks. It compares placebo (dotted line with circles) to Fesoterodine fumarate 4 mg (dashed line with triangles) and 8 mg (solid line with squares). Both Fesoterodine doses reduce episodes more than placebo over time.*

FDA Label Image

Figure 3 (Fesoterodine Fumarate Extended Release Tablets 4)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 2),' displaying mean change from baseline in micturitions over 12 weeks. The graph compares placebo, Fesoterodine fumarate 4 mg, and 8 mg groups, showing decrease trends with different markers for each group.*

FDA Label Image

Figure 4 (Fesoterodine Fumarate Extended Release Tablets 5)

Line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 2)' showing mean change from baseline in urge incontinence episodes over 12 weeks. It compares placebo (dotted line with circles), Fesoterodine fumarate 4 mg (dashed line with triangles), and Fesoterodine fumarate 8 mg (solid line with squares). Both Fesoterodine doses show greater reductions compared to placebo over time.*

FDA Label Image

4 mg 30 Count Label (Fesoterodine Fumarate Extended Release Tablets 6)

Label for Fesoterodine Fumarate Extended-Release Tablets 4 mg by Amneal Pharmaceuticals LLC. The oral tablet package contains 30 tablets. Storage instructions note temperature limits and moisture protection. The label includes an image of a blue, oval-shaped tablet marked with 'A59', with a barcode and distributor information from Amneal Pharmaceuticals in Bridgewater, NJ.*

FDA Label Image

8 mg 30 Count Label (Fesoterodine Fumarate Extended Release Tablets 7)

Label for Fesoterodine Fumarate Extended-Release Tablets, 8 mg strength, oral extended-release film-coated tablets. The label includes NDC 65162-370-03, a quantity of 30 tablets, and indicates dispensing with a Patient Information leaflet. Distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ. Storage instructions and barcode are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.